These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1671883)

  • 21. Experimental AIDS drug, d4T, now available to patients in critical need.
    Ann Allergy; 1993 Apr; 70(4):A19. PubMed ID: 8385427
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine.
    Jacobson MA; Abrams DI; Volberding PA; Bacchetti P; Wilber J; Chaisson RE; Crowe S; Howard W; Moss A
    J Infect Dis; 1989 Jun; 159(6):1029-36. PubMed ID: 2566637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemokine (C-C motif) receptor 5 entry inhibitors: new class of drugs for acquired immune deficiency syndrome.
    Jacovina A; New M
    Mt Sinai J Med; 2008; 75(3):297-8. PubMed ID: 18704982
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA 'pushing envelope' on AIDS drug.
    Cotton P
    JAMA; 1991 Aug; 266(6):757-8. PubMed ID: 1907668
    [No Abstract]   [Full Text] [Related]  

  • 25. Overhaul at the FDA begins.
    Science; 1992 Apr; 256(5055):313. PubMed ID: 1566081
    [No Abstract]   [Full Text] [Related]  

  • 26. [Another AIDS drug. Azidothymidine--dideoxycytidine].
    Moosmann EB
    Fortschr Med; 1992 Jun; 110(18):28-30. PubMed ID: 1353746
    [No Abstract]   [Full Text] [Related]  

  • 27. Impaired immunity in AIDS. The mechanisms responsible and their potential reversal by antiviral therapy.
    Ruegg CL; Engleman EG
    Ann N Y Acad Sci; 1990; 616():307-17. PubMed ID: 1981824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DdI approval offers second chance.
    Albert SG
    Am Pharm; 1991 Dec; NS31(12):6. PubMed ID: 1763779
    [No Abstract]   [Full Text] [Related]  

  • 29. Row over controversial new AIDS drug.
    Buderi R
    Nature; 1989 Sep; 341(6240):267. PubMed ID: 2677738
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
    Ebert S; Gockel K; Horowitz S; Weber P; Vogelman B; Graziano F
    Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fast track for AIDS and cancer drugs.
    Gershon D
    Nature; 1990 Aug; 346(6286):685. PubMed ID: 2388690
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of beta 2-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection.
    Anderson RE; Lang W; Shiboski S; Royce R; Jewell N; Winkelstein W
    Arch Intern Med; 1990 Jan; 150(1):73-7. PubMed ID: 1967523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4 counts as surrogate markers for progression to AIDS.
    Hirschel B
    Ann Intern Med; 1994 Jan; 120(1):87; author reply 88. PubMed ID: 7902687
    [No Abstract]   [Full Text] [Related]  

  • 34. Treating seriously ill patients with experimental drugs.
    Palumbo FB
    Pharm Res; 1990 Oct; 7(10):988-9. PubMed ID: 2281044
    [No Abstract]   [Full Text] [Related]  

  • 35. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Serum adenosine deaminase in human immunodeficiency virus infection. Its relationship with CD4+ lymphocytes and beta 2-microglobulin].
    Iñigo MA; Ruiz López de Tejada M; Torres-Tortosa M; Sánchez-Porto A; Ugarte I; García de Lomas E; Morán Nestares A
    Med Clin (Barc); 1992 Dec; 99(20):766-8. PubMed ID: 1361013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative study of various biological markers in HIV 1 infection].
    Serra JE; Pombo V; Côrte-Real R; da Cunha S; Meliço-Silvestre A
    Acta Med Port; 1993 Jan; 6(1):5-9. PubMed ID: 8097351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory hierarchies.
    Oldham RK
    Mol Biother; 1988; 1(1):3-6. PubMed ID: 3267370
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.
    Daemmrich A; Krucken G
    Sci Cult (Lond); 2000 Dec; 9(4):505-34. PubMed ID: 15988846
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.